Major Investor Group Reduces Stake in Bolt Biotherapeutics
Summary
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, reported selling approximately $151,515 worth of Bolt Biotherapeutics common stock, reducing their collective ownership.
Key Events
-
Investor Group Sells Shares
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, sold 24,801 shares of common stock.
-
Significant Transaction Value
The total value of the shares sold amounted to approximately $151,515.
-
Reduced Ownership
The sales occurred between January 28, 2026, and February 13, 2026, leading to a reduction in the group's overall percentage ownership.
Analysis
This Schedule 13D/A filing indicates that a significant investor group, comprising Nan Fung Group Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., and related entities, has reduced its stake in Bolt Biotherapeutics. The group collectively sold 24,801 shares for a total value of approximately $151,515 between January 28, 2026, and February 13, 2026. While the absolute dollar value is modest, it represents a notable percentage of the company's small market capitalization. The sales occurred at prices ranging from $4.96 to $6.85 per share. This reduction in ownership by a major institutional holder could signal a shift in their investment thesis or a move to rebalance their portfolio.
At the time of this filing, BOLT was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $4.41 to $10.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.